Delving into the Latest Updates on B-013 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesDigestive System Disorders+ [2]

Active Indication

Triple Negative Breast CancerFallopian Tube CarcinomaPlatinum-Resistant Ovarian Carcinoma+ [6]

Inactive Indication-

Originator Organization

Shanghai Pharmaceuticals Holding Co., Ltd.

Active Organization

Shanghai Jiaolian Drug Development Co. Ltd.

Shanghai Pharmaceuticals Holding Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Login to view timeline

This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

Start Date06 Dec 2022

Sponsor / Collaborator

Shanghai Jiaolian Drug Development Co. Ltd.

[+1]

100 Clinical Results associated with B-013

Login to view more data

100 Translational Medicine associated with B-013

Login to view more data

100 Patents (Medical) associated with B-013

Login to view more data

83

Literatures (Medical) associated with B-013

17 Oct 2023·ChemMedChem

Synthesis of Quinazolin‐2,4,6‐triamine Derivatives as Non‐purine Xanthine Oxidase Inhibitors and Exploration of Their Toxicological Potential**

Article

Author: Lopez-Sanchez, Marcela A ; Aguayo-Ortiz, Rodrigo ; Figueroa-Figueroa, Diego I ; Hernandez-Cruz, Estefani ; Hernandez-Luis, Francisco ; Del Carmen Garcia-Rodriguez, María

AbstractIn this work, a new set of quinazolin‐2,4,6‐triamine derivatives were synthesized to explore their potential biological activity as xanthine oxidase (XO) inhibitors, superoxide scavengers and screening of their toxicological profile. Among all the synthesized compounds, B1 exhibited better inhibitory activity against bovine xanthine oxidase (bXO) than allopurinol (IC50=1.56 μM and IC50=6.99 μM, respectively). As superoxide scavengers, B1, B2 and B13 exhibited a better effect than allopurinol (97.3 %, 82.1 %, 87.4 % and 69.4 %, respectively). Regarding the toxicological profile, B1 was less cytotoxic than methotrexate on HCT‐15 cancer cells. Apoptosis results obtained in cells of female and male mice, showed that B1 and B2 presented a similar behaviour to CrO3 (positive control) with respect to the average frequency to induce apoptosis; while B13 apoptosis induced effect was similar to DMSO and control group. Finally, B1, B2, B13 did not induce genotoxicity in a micronuclei murine model compared to CrO3.

18 Jul 2023·Natural Product ResearchQ3 · CHEMISTRY

Synthesis and antifungal activity of novel chiral indole analogues

Q3 · CHEMISTRY

Article

Author: Zheng, Shaojun ; Tang, Bing ; Tan, Yi ; Dai, Huihui ; Lin, Chuansong ; Jiang, Qiaoju ; Fang, Yue ; Wu, Wenbin

Starting from L-tryptophan, 19 new N-substituted chiral indole analogs were synthesized. The prepared compounds were evaluated for biological activity against Sclerotinia sclerotiorum, Alternaria solani, Verticillium dahliae, Colletotrichum orbiculare, Cytospora juglandis and Curvularia lunata. The preliminary bioassays showed that most of the synthesized compounds exhibited fungicidal activity. Compound b13 in particular exhibited significant antifungal activity against Verticillium dahliae and Sclerotinia sclerotiorum, with the MIC value of 1.95 µg mL^-1. Compound b13 also showed excellent activity against six plant pathogen fungi, and was identified as the most active on the biological assays, and will be studied further.

01 Jun 2023·Bulletin of experimental biology and medicine

Pharmacological Properties of Sulfonamide Derivatives, New Inhibitors of Carbonic Anhydrase.

Article

Author: Shetnev, A A ; Volkhin, N N ; Tyushina, A N ; Korsakov, M K ; Khokhlov, A L ; Vdovichenko, V P ; Fedorov, V N

Selective blocking of individual isoforms of carbonic anhydrase (CA) is now one of the main directions in the development of its inhibitors. The new 1,2,4-oxadiazole-containing sulfonamides B12 and B13 predominantly block CA II and CA IX. The study of acute toxicity of B12 and B13 showed their safety. Substance B13 caused a relatively short-term, but rapid (within 30 min) decrease in the intraocular pressure in rabbits, which indicates the promise of its use for the emergency decrease in the intraocular pressure in medical practice. Analysis of the effects of sulfonamides on the functions of CNS showed that compound B12 probably exhibit tranquilizing activity; B13 is promising for the creation of drugs that have an antidepressant effect and at the same time increase the mental and physical performance.

100 Deals associated with B-013

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Triple Negative Breast Cancer	Phase 3	-	Shanghai Pharmaceuticals Holding Co., Ltd.	23 Aug 2022
Fallopian Tube Carcinoma	Phase 2	CN	Shanghai Pharmaceuticals Holding Co., Ltd.	11 Jul 2024
Platinum-Resistant Ovarian Carcinoma	Phase 2	CN	Shanghai Pharmaceuticals Holding Co., Ltd.	11 Jul 2024
Platinum-Resistant Primary Peritoneal Carcinoma	Phase 2	CN	Shanghai Pharmaceuticals Holding Co., Ltd.	11 Jul 2024
Platinum-Resistant Fallopian Tube Carcinoma	Phase 2	CN	Shanghai Jiaolian Drug Development Co. Ltd.	20 Jun 2024
Neoplasms	Phase 2	US	Shanghai Pharmaceuticals Holding Co., Ltd.	21 Jul 2022
Recurrent Platinum-Resistant Fallopian Tube Carcinoma	IND Approval	CN	Shanghai Jiaolian Drug Development Co. Ltd.	30 Jan 2024
Recurrent Platinum-Resistant Ovarian Carcinoma	IND Approval	CN	Shanghai Jiaolian Drug Development Co. Ltd.	30 Jan 2024
Recurrent Platinum-Resistant Primary Peritoneal Carcinoma	IND Approval	CN	Shanghai Jiaolian Drug Development Co. Ltd.	30 Jan 2024